Highly efficient CD4+ T cell targeting and genetic recombination using engineered CD4+ cell-homing mRNA-LNPs
István Tombácz(University of Pennsylvania), Hamideh Parhiz(Translational Therapeutics (United States)), Vladimir R. Muzykantov(Translational Therapeutics (United States)), Amir Yadegari(Shahid Beheshti University of Medical Sciences), Hamna Shahnawaz(University of Pennsylvania), Vladimir V. Shuvaev(California University of Pennsylvania), Dorottya Laczkó(University of Pennsylvania), Ying K. Tam(Arbutus Biopharma (Canada)), Norbert Pardi(University of Pennsylvania), Ambika Natesan(University of Pennsylvania), Drew Weissman(California University of Pennsylvania), Mohamad‐Gabriel Alameh(Children's Hospital of Philadelphia), Tyler E. Papp(Translational Therapeutics (United States)), Hiromi Muramatsu(University of Pennsylvania), Barbara L. Mui(Arbutus Biopharma (Canada))
Cited by 272
Related Papers
mRNA vaccines — a new era in vaccinology
|Nature Reviews Drug Discovery|2018|4.4k
Rational design of cationic lipids for siRNA delivery
|Nature Biotechnology|2010|1.8k
The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs
|Nature Nanotechnology|2019|1.6k
Maximizing the Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing In Vivo**
|Angewandte Chemie International Edition|2012|1.2k
CAR T Cells Produced in vivo to Treat Cardiac Injury
|HAL (Le Centre pour la Communication Scientifique Directe)|2023|940